Bilateral Wilms Tumors That Grow During Chemo Mostly Stromal-Predominant
By Elana Gotkine HealthDay Reporter
WEDNESDAY, April 17, 2024 -- Bilateral Wilms tumors (BWTs) that increase in size during neoadjuvant chemotherapy, especially in younger patients, are most often stromal-predominant, according to a study published online March 27 in the Journal of the National Cancer Institute.
Colton Duncan, from the Dana-Farber Cancer Institute/Boston Children's Hospital, and colleagues conducted a retrospective, single-institution study to examine whether initial chemotherapy response is associated with tumor histology among patients with BWT who underwent surgery from January 2000 to March 2022. A total of 68 patients were eligible for the study.
The researchers found that the odds ratio for being stromal-predominant versus any other histological subtype was 19.5 for tumors that increased in size. Compared with all other histologic subtypes, patients with stromal-predominant tumors had the youngest age at diagnosis (mean, 18.8 months). For confirming stromal-predominant histology, the predictive value of a tumor growing, combined with patient age younger than 18 months, was 85.7 percent.
"Wilms tumor with unfavorable outcomes actually do generally respond well, at least initially, to the chemotherapy," coauthor Andrew Davidoff, M.D., from St. Jude Children's Research Hospital in Memphis, Tennessee, said in a statement. "Whereas, at the other end of the spectrum, we have this extremely favorable type, this stromal-predominant tumor, that has typically good outcomes despite not responding very well to the chemotherapy."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
ACG: 2000 to 2022 Saw Rise in Early-Onset CRC Mortality in the United States
THURSDAY, Oct. 31, 2024 -- Early-onset colorectal cancer (EO-CRC) mortality rose in the United States over the past two decades, most notably in patients aged 20 to 44 years...
Cell-Free Blood DNA Tests Less Effective Than Other CRC Screening
WEDNESDAY, Oct. 30, 2024 -- Cell-free DNA blood tests (cf-bDNA) may be more costly and less effective for colorectal cancer (CRC) screening than other screening modalities...
American College of Surgeons, Oct. 19-22
The annual meeting of the American College of Surgeons was held this year from Oct. 19 to 22 in San Francisco and attracted participants from around the world, including...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.